Rituximab for Rheumatoid Arthritis Following TNF-alpha Inhibitor Associated Splenic Tuberculosis
Journal of Rheumatic Diseases
; : 108-112, 2013.
Article
Dans Ko
| WPRIM
| ID: wpr-50813
Responsable en Bibliothèque :
WPRO
ABSTRACT
One of the most important adverse effects of a tumor necrosis factor (TNF)-alpha inhibitor is the reactivation of tuberculosis. Most of them occur in the lung, but sometimes they can be found in other organs. Moreover, the proper management of active rheumatoid arthritis (RA) in patients with anti-TNF-alpha associated tuberculosis is still in debate. We present the case of a seropositive RA patient who showed good response with rituximab, an anti-CD20 monoclonal antibody, after developing splenic tuberuculosis, following treatment with TNF-alpha inhibitor. Confirming a diagnosis of splenic tuberculosis is difficult and can be delayed due to its nonspecific symptoms and rare occurrence. This case suggests that splenic tuberculosis should be doubted in RA patients treated with TNF-alpha inhibitor, and that rituximab may be considered as an alternative treatment option in RA patients with anti-TNF-alpha associated tuberculosis.
Texte intégral:
1
Indice:
WPRIM
Sujet Principal:
Polyarthrite rhumatoïde
/
Tuberculose
/
Tuberculose splénique
/
Facteur de nécrose tumorale alpha
/
Anticorps monoclonaux d'origine murine
/
Rituximab
/
Poumon
Limites du sujet:
Humans
langue:
Ko
Texte intégral:
Journal of Rheumatic Diseases
Année:
2013
Type:
Article